Showing results (71-80 of 110) with videos related to
Sort By:
Pageof 11
Future Oncology (London, England)|February 25, 2015
Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patientsG Mustacchi, F Puglisi, A M Molino, et al.Breast (Edinburgh, Scotland)|February 27, 2010
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancerM Venturini, C Bighin, F Puglisi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2019
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)T Bachelot, E Ciruelos, A Schneeweiss, et al.International Journal of Obesity (2005)|May 26, 2011
The effects of weight loss due to gastric banding and lifestyle modification on red blood cell aggregation and deformability in severe obese subjectsP Capuano, G Catalano, G Garruti, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2008
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancerF Puglisi, G G Cardellino, D Crivellari, et al.Cancer Treatment Reviews|June 26, 2018
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtypeL Gerratana, D Basile, G Buono, et al.Neurobiology of Disease|February 27, 2016
Exposure to low-dose rotenone precipitates synaptic plasticity alterations in PINK1 heterozygous knockout miceG Martella, G Madeo, M Maltese, et al.Journal of Cancer Policy|July 28, 2021
Transformation of Cancer Care during and after the COVID Pandemic, a point of no return. The Experience of ItalyR Tarricone, E Listorti, V Tozzi, et al.Breast (Edinburgh, Scotland)|September 6, 2024
Neoadjuvant chemotherapy for breast cancer in Italy: A Senonetwork analysis of 37,215 patients treated from 2017 to 2022A De Luca, M I Amabile, F Santori, et al.Breast Cancer Research and Treatment|March 15, 2017
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trialsM V Dieci, A Frassoldati, D Generali, et al.Pageof 11